Noronex Ltd.

As of June 30, 2024, Noronex Ltd. carries a market capitalization of 5.38M, placing it among publicly traded companies globally. Its enterprise value stands at 4.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Noronex Ltd. has 488.69M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Noronex Ltd. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Noronex Ltd. posted a negative return on equity (ROE) of -85.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -70.27, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Noronex Ltd.'s stock has declined approximately 31.25% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -2.57M, while operating income came in at -2.57M.

These figures are as of June 30, 2024. Total book value stands at 3.02M, with working capital of 510,645.00 providing operational flexibility.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -46.01, meaning Noronex Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Noronex Ltd.'s most recent stock split took place on July 5, 2023 with a 43:45 split ratio.